Related Experiment Video
Updated: Mar 29, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10.4K
Talimogene Laherparepvec: First Global Approval.
1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
Drugs
|December 2, 2015
Summary
Talimogene laherparepvec, an oncolytic virus therapy, is approved for treating melanoma. This genetically modified herpes simplex virus selectively replicates in tumor cells, stimulating anti-tumor immunity for local treatment.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Talimogene laherparepvec is an oncolytic viral therapy developed for various cancers, including malignant melanoma.
- It is a genetically modified, live, attenuated herpes simplex virus type 1.
Purpose of the Study:
- To summarize the development milestones of talimogene laherparepvec.
- To highlight its first approval for malignant melanoma treatment.
Main Methods:
- Genetically modified herpes simplex virus type 1.
- Intralesional administration for selective viral replication in tumor cells.
- Stimulation of systemic anti-tumor immunity.
Main Results:
- First genetically modified oncolytic viral therapy approved in the USA (October 2015) for unresectable melanoma.
- Approved for local treatment of cutaneous, subcutaneous, and nodal lesions in recurrent melanoma.
- Recommended for approval in the EU for unresectable metastatic melanoma.
Conclusions:
- Talimogene laherparepvec represents a significant advancement in oncolytic viral therapy for melanoma.
- Further evaluations are ongoing for neoadjuvant or combination therapy in melanoma and other cancers like soft tissue sarcoma and liver cancer.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
02:56Treatment Resistent Cancers
1.5K
1.5K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:57Targeted Cancer Therapies
1.8K
1.8K
01:26FDA Approved Drugs: Changes to Approved Drugs
328
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
328
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K